{
    "clinical_study": {
        "@rank": "41790", 
        "acronym": "CALLISTO", 
        "arm_group": {
            "arm_group_label": "Omigapil", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to establish the pharmacokinetic profile of omigapil in\n      paediatric and adolescent patients with CMD and to evaluate the safety and tolerability of\n      omigapil."
        }, 
        "brief_title": "Pharmacokinetic Study With Assessment of Safety and Tolerability of Omigapil in Children and Adolescents With Congenital Muscular Dystrophy", 
        "condition": "Congenital Muscular Dystrophy", 
        "condition_browse": {
            "mesh_term": "Muscular Dystrophies"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ambulatory and non-ambulatory patients from age 5 - 16 years with a clinical picture\n             (see below) consistent with Ullrich CMD or MDC1A (LAMA2/merosin deficient CMD)\n\n          -  Under regular review at a neuromuscular centre\n\n          -  On adequate double-barrier contraception (if of child-bearing potential)\n\n          -  Stable on any allowed concomitant medications for 1 month prior to run in phase\n\n          -  FVC < 80% of the predicted value at Screening and Baseline visit(s)\n\n        For patients with Ullrich CMD - required clinical picture:\n\n        \u2022 Muscle weakness: inability to walk or, if patient is still ambulatory, inability to run\n        and > 5 s for 10 m walk\n\n        Genetics and Pathology:\n\n          -  Molecular diagnosis of collagen VI related myopathy, defined by one dominant or two\n             recessive COL6A1, COL6A2 or COL6A3 mutation(s) known to cause the clinical picture,\n             OR\n\n          -  Histological diagnosis showing (i) absent or significantly decreased  expression of\n             collagen VI in muscle (overall reduction or basal lamina specific) or (ii) absent or\n             significantly abnormal matrix in skin fibroblast culture\n\n        For patients with LAMA2 deficient CMD (MDC1A) - required clinical picture:\n\n        \u2022 Muscle weakness: Inability to walk; if patient is still ambulatory, inability to run and\n        > 5 s for 10 m walk.\n\n        Genetics and Pathology:\n\n          -  Either: 2 identified pathologic or probable pathologic mutations in LAMA2 gene OR\n\n          -  1 identified pathologic or probable pathologic mutation in LAMA 2 gene with evidence\n             of decrease in laminin alpha 2 staining on muscle or skin biopsy OR\n\n          -  Evidence of decrease in laminin alpha 2 staining on muscle or skin biopsy with\n             matching clinical phenotype and no suspicion of aDG-RD\n\n        Exclusion Criteria:\n\n          -  Use of any investigational drug other than the study medication within 3 months of\n             study start.\n\n          -  Recurrent hospitalisation for chest infections in previous 2 years (\u22652 per year)\n\n          -  Patients with respiratory parameters currently affected by concomitant medications or\n             conditions (conduct baseline assessments when the patient has recovered and no longer\n             taking acute medication)\n\n          -  Any need for surgery (scoliosis, gastrostomy, other) in the preceding 6 months or\n             foreseen during the course of the study.\n\n          -  Any intercurrent significant medical condition which in the opinion of the\n             Investigator or the study Medical Monitor is suspected of potentially affecting the\n             patient's safety or compliance with the study procedures\n\n          -  Failure to thrive, defined as:\n\n               -  Falling 20 percentiles (20/100) in body weight in the 3 months preceding\n                  Screening/Baseline\n\n               -  In patients below the 3rd percentile, any further drop in body weight percentile\n                  in the 3 months preceding Screening/Baseline\n\n          -  Weight less than 17kg at Baseline\n\n          -  Morbidly obese or grossly overweight (\u226586 percentile BMI in children)\n\n          -  History of epilepsy or on antiepileptic medication at Screening/Baseline\n\n          -  Diabetes\n\n          -  FVC% predicted <30%\n\n          -  On Non Invasive Ventilation (NIV) Expectation of non-compliance with study procedures\n             (i.e. study medication intake and/or PK blood sampling) excluding exploratory\n             efficacy assessments\n\n          -  Intake of prohibited medication (as listed in Appendix A of the protocol)\n\n          -  Patients with renal impairment defined as urinary protein concentration \u2265 0.2 g/L\n\n          -  Patients with moderate to severe hepatic impairment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "16 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805024", 
            "org_study_id": "SNT-I-015"
        }, 
        "intervention": {
            "arm_group_label": "Omigapil", 
            "intervention_name": "Omigapil", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 6, 2013", 
        "number_of_arms": "1", 
        "official_title": "Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study anaLyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil", 
        "other_outcome": {
            "measure": "Tertiary objective: to establish the feasibility of conducting disease-relevant clinical assessments in paediatric and adolescent patients with CMD to aid in the design of future studies", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 12 and 16"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Primary objective: to establish the pharmacokinetic profile of omigapil at a range of doses in paediatric and adolescent patients with CMD.", 
            "safety_issue": "No", 
            "time_frame": "Week 4 and Week  8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805024"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Secondary objective: to evaluate the safety and tolerability of omigapil at a range of doses in paediatric and adolescent patients.", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline, Week 4, 8 and 12"
        }, 
        "source": "Santhera Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Santhera Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}